- Active ingredient
- methylprednisolone sodium succinate
- Strength
- 500 mg
- Form
- tablet
- Manufacturer
- pfizer
- Route
- oral.solid
Uses
Indicated by intravenous or intramuscular route when oral therapy is not feasible, for severe allergic conditions, inflammatory and autoimmune diseases, dermatologic diseases, respiratory conditions such as asthma, and as part of immunosuppressive regimens.
Do not use if
Contraindicated in systemic fungal infections and in patients with known hypersensitivity to methylprednisolone or any excipient. The 40 mg formulation containing lactose monohydrate is contraindicated in patients with cow's milk allergy.
Side effects
May cause cardiovascular effects including bradycardia and arrhythmias, leukocytosis, anaphylactic reactions, endocrine disturbances such as hyperglycemia and adrenal suppression, gastrointestinal bleeding, osteoporosis with prolonged use, and neuropsychiatric effects.
Warnings
Serious neurologic events, including spinal cord infarction and death, have been reported with epidural corticosteroid injection; this route is not approved. Prolonged use may cause adrenal suppression, osteoporosis, and increased infection susceptibility. Monitor blood glucose in diabetics.
How it works
Methylprednisolone sodium succinate is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive activity. It binds intracellular glucocorticoid receptors, modulating gene transcription and suppressing the synthesis of inflammatory mediators.
Storage
Protect from light. Store unreconstituted product at controlled room temperature between 20°C and 25°C. Use reconstituted solution within 48 hours if kept refrigerated at 2°C to 8°C.